Anaplastic diffuse large B-cell lymphoma
CD30-positive diffuse large B-cell lymphoma
Centroblastic diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma, subtype not specified
Immunoblastic diffuse large B-cell lymphoma
Plasmablastic diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma, subtype not specified
T-cell rich diffuse large B-cell lymphoma
A non-hodgkin lymphoma characterized by a diffuse proliferation of predominantly large neoplastic b lymphocytes. It is the most frequently seen type of non-hodgkin lymphoma, representing 30%-40% of the cases. Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, and anaplastic lymphoma. Subtypes/entities include t-cell/histiocyte rich large b-cell lymphoma, primary diffuse large b-cell lymphoma of the central nervous system, plasmablastic lymphoma, primary cutaneous diffuse large b-cell lymphoma, leg type, and alk-positive large b-cell lymphoma.
A non-hodgkin lymphoma characterized by a diffuse proliferation of predominantly large neoplastic b lymphocytes. It is the most frequently seen type of non-hodgkin lymphoma, representing 30%-40% of the cases. Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, t-cell/histiocyte rich lymphoma, anaplastic lymphoma, plasmablastic lymphoma, and diffuse large b-cell lymphoma with expression of full-length alk. who, 2001)
A type of b-cell non-hodgkin lymphoma cancer of the immune system) that is usually aggressive fast-growing). It is the most common type of non-hodgkin lymphoma, and is marked by rapidly growing tumors in the lymph nodes, spleen, liver, bone marrow, or other organs. Other symptoms include fever, night sweats, and weight loss. There are several subtypes of diffuse large b-cell lymphoma.
Malignant lymphoma composed of large b lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of b-lymphocytes at midstage in the process of differentiation.
C83.3 should not be used for reimbursement purposes as there are multiple codes below it that contain a greater level of detail.
The 2023 edition of ICD-10-CM C83.3 became effective on October 1, 2022.
This is the American ICD-10-CM version of C83.3 – other international versions of ICD-10 C83.3 may differ.